HIV & Hypogonadism
From AIDS-wasting-era androgen deficiency to the modern ART context
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not an FDA product (testosterone HAS niche approval contexts; see notes)
Reference only. Not medical advice.
What can go wrong
The interpretive risk is anachronism: quoting pre-ART wasting-era prevalence figures for a virally suppressed patient on modern therapy overstates the problem. In treated HIV, low testosterone should be worked up for ordinary causes (age, metabolic syndrome, lipodystrophy, other drugs) rather than assumed to be virus-driven. Exogenous testosterone suppresses fertility, a relevant consideration for reproductive-age men with HIV.
This is something to take to a clinician. The Atlas can tell you what is known about hiv & hypogonadism in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Hypogonadism was strikingly common in men with HIV during the pre-antiretroviral (pre-ART) AIDS-wasting era - chronic illness, weight loss, and direct effects suppressed testosterone in a large fraction of patients, and testosterone (and anabolic agents like oxandrolone) were used to combat AIDS wasting syndrome. In the modern combination-ART era, severe wasting is uncommon and prevalence of frank hypogonadism is much lower, but low testosterone is still seen more often than in the general population, now associated more with aging, comorbidity, metabolic changes, and lipodystrophy than with wasting. The history is a useful caution about reading old prevalence figures into today's context.
In the wasting era, hypogonadism was rampant and testosterone was a wasting therapy. On modern ART, the picture is quieter but not gone.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
In advanced untreated HIV, hypogonadism arose from the systemic effects of chronic severe illness - cytokine-driven central HPG suppression, weight loss, opportunistic infections affecting the gonadal axis, and sometimes direct effects - producing both central and primary patterns. In that context, testosterone and selected anabolic steroids (e.g. oxandrolone) were studied and used to counter AIDS wasting syndrome, aiming to preserve lean body mass. With effective combination ART, the wasting-driven mechanism largely receded; residual low testosterone in treated HIV is now more attributable to ordinary aging, metabolic syndrome, comorbid illness, and antiretroviral-associated lipodystrophy/metabolic changes than to the virus itself.
Reading the era correctly
The honest interpretive point: prevalence figures for HIV-associated hypogonadism are heavily era-dependent, and quoting pre-ART numbers for a virally suppressed patient on modern therapy would mislead. In the wasting era, hypogonadism was a prominent, illness-driven phenomenon and testosterone/anabolics had a defensible role in preserving lean mass against AIDS wasting syndrome - one of the few historically legitimate clinical uses of anabolic strategies. Today, a man with well-controlled HIV who has low testosterone most likely has it for the same reasons other men do (age, central obesity, metabolic syndrome, other drugs), plus a possible contribution from lipodystrophy and metabolic effects of some regimens. The category lesson: low T in HIV is a marker to interpret in clinical and historical context, not a fixed feature of the diagnosis.
What it does to fertility
Exogenous testosterone suppresses spermatogenesis; relevant for HIV-positive men of reproductive age, who also have safe conception options under modern care.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total/free testosterone
- LH/FSH
- Assessment of comorbidity and ART regimen
What people get wrong
Often saidHIV always causes severe low testosterone
ActuallyThat reflects the pre-ART wasting era. With effective modern antiretroviral therapy, severe wasting is uncommon and frank hypogonadism is much less prevalent - residual low T is now tied mostly to aging, metabolic factors, and lipodystrophy.
Often saidAnabolic steroids in HIV were always quackery
ActuallyIn the AIDS-wasting era, testosterone and agents like oxandrolone had a legitimate, studied role in preserving lean body mass against wasting syndrome - one of the historically defensible clinical uses of anabolic strategies.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Pre-ART era
- High hypogonadism prevalence amid AIDS wasting
- Wasting-era therapy
- Testosterone and oxandrolone used against wasting
- Modern ART era
- Lower prevalence; tied to age/comorbidity/lipodystrophy
- Pattern
- Mixed central and primary
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about HIV & Hypogonadism. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Oxandrolone/testosterone AIDS-wasting trials1990s
Anabolic and androgen therapy studied to preserve lean body mass in AIDS wasting syndrome in the pre-/early-ART era
Bhasin et al. testosterone-in-HIV work1990s-2000s
Examined testosterone replacement effects on body composition and function in hypogonadal HIV-infected men